A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

Phase 2

Completed

• Conditions: Hidradenitis Suppurativa (HS)
• Interventions: Drug: Spesolimab

• Registration Number: NCT06241573
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).

The purpose of this study is to find out how well people tolerate spesolimab and whether it helps people with HS in the long-term. For about 1.5 years, participants get spesolimab injections under the skin every 2 weeks.

Participants are in the study for about 2 years. During this time, participants have 41 visits. 24 visits are done at the study site. 17 visits can be done by video call at the participant's home. At study visits, doctors check the severity of the participant's HS and collect information on any health problems of the participants.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-01-29
• Study First Submitted QC: 2024-01-29
• Study First Posted: 2024-02-05
• Study Start: 2024-05-08
• Status Verified: 2025-04
• Primary Completion: 2025-04-11
• Study Completion: 2025-04-11
• Last Update Submitted: 2025-04-28
• Last Update Posted: 2025-04-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

1. Signed and dated written informed consent in accordance with ICH Harmonized Guideline for Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
2. Participants must be within the defined Residual Effect Period corresponding to 16 weeks since last spesolimab administration.
3. Participants who have completed treatment in the parent hidradenitis suppurativa (HS) spesolimab trial (1368-0098 (NCT05819398) or 1368-0100) without premature discontinuation and are willing and able to continue treatment in this trial.
4. Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.

Exclusion Criteria

1. Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
2. Use of any drug considered by the investigator likely to interfere with the safe conduct of the trial since the last visit of the parent trials.
3. Use of immunomodulatory biologics or investigational agents since the last visit of the parent trials.
4. Participants who require / intend to use certain restricted medications such as immunomodulatory biologics or other investigational drugs/devices during the course of the trial.
5. Relevant chronic or acute infections including human immunodeficiency virus (HIV) and viral hepatitis. The corresponding laboratory tests will be performed at Visit 1. A participant can be re-screened if the participant was treated and is cured from the acute infection.

Further exclusion criteria apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Patients treated in Part I of parent trial 1368-0098 (NCT05819398)	Spesolimab	-
Patients treated in Part II of parent trial 1368-0098 (NCT05819398)	Spesolimab	-
Patients treated in parent trial 1368-0100	Spesolimab	-

Primary Outcome Measures

Name	Time	Method
Occurrence of treatment emergent adverse events (TEAE)	up to 92 weeks

Trial Locations

Locations (36)

ASMC-IPSMC-skin and Veneral Diseases; 🇧🇬 Sofia, Bulgaria

Clinical Trials Research Institute; 🇺🇸 Thousand Oaks, California, United States

STAT Research; 🇦🇷 Caba, Argentina

Hospital Italiano de Buenos Aires; 🇦🇷 Caba, Argentina

Kurume University Hospital; 🇯🇵 Fukuoka, Kurume, Japan

First OC Dermatology; 🇺🇸 Fountain Valley, California, United States

Dermatology Research Associates; 🇺🇸 Los Angeles, California, United States

Integrative Skin Science and Research-Sacramento-69402; 🇺🇸 Sacramento, California, United States

Medical Center "Kordis"; 🇧🇬 Pleven, Bulgaria

Hospital Alemán; 🇦🇷 Capital Federal, Argentina

Holdsworth House Medical Practice; 🇦🇺 Sydney, New South Wales, Australia

Alfred Hospital; 🇦🇺 Melbourne, Victoria, Australia

Guelph Dermatology Research; 🇨🇦 Guelph, Ontario, Canada

SimcoDerm Medical and Surgical Dermatology Centre; 🇨🇦 Barrie, Ontario, Canada

Dr. S. K. Siddha Medicine Professional Corporation; 🇨🇦 Newmarket, Ontario, Canada

Hautmedizin Saar; 🇩🇪 Merzig, Germany

HOP Privé Antony; 🇫🇷 Antony, France

HOP Edouard Herriot; 🇫🇷 Lyon, France

Fachklinik Bad Bentheim; 🇩🇪 Bad Bentheim, Germany

Ogaki Municipal Hospital; 🇯🇵 Gifu, Ogaki, Japan

The University of Tokyo Hospital; 🇯🇵 Tokyo, Bunkyo-ku, Japan

Nihon University Itabashi Hospital; 🇯🇵 Tokyo, Itabashi-ku, Japan

Tokyo Medical University Hospital; 🇯🇵 Tokyo, Shinjuku-ku, Japan

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Hospital of Lithuanian University of Health Sciences Kauno Klinikos; 🇱🇹 Kaunas, Lithuania

Vilnius University Hospital, Santariskiu; 🇱🇹 Vilnius, Lithuania

Hospital Pulau Pinang-Pulau Pinang-21953; 🇲🇾 Georgetown Pulau Pinang, Malaysia

Hospital Sultan Ismail; 🇲🇾 Johor Bahru, Malaysia

Hospital Kuala Lumpur; 🇲🇾 Kuala Lumpur, Malaysia

Sarawak General Hospital; 🇲🇾 Kuching, Malaysia

Sunway Medical Centre; 🇲🇾 Selangor Darul Ehsan, Malaysia

Non-Public Health Care Facility LABDERM; 🇵🇱 Ossy, Poland

Provita Clinic; 🇵🇱 Warsaw, Poland

Royalderm; 🇵🇱 Warszawa, Poland

National University Hospital-Singapore-42005; 🇸🇬 Singapore, Singapore

Hospital Miguel Servet; 🇪🇸 Zaragoza, Spain